Navigation Links
Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
Date:6/24/2011

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 patients that showed the addition of BYETTA® (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings will be presented in a poster session at the 71st Scientific Sessions of the American Diabetes Association in San Diego on June 25 from 11:30 a.m. to 1:30 p.m. PDT.

The retrospective analysis used data from the GE Healthcare Centricity electronic medical record to analyze the likelihood of heart failure for BYETTA in combination with certain other diabetes treatments compared with control groups of patients not treated with BYETTA. Across all therapies, patients who received BYETTA were 54 percent less likely to experience heart failure compared to patients not treated with BYETTA.

"Compared with the general population, people with diabetes have an increased risk of heart disease, with at least double the risk of developing heart failure. That's why it is imperative that we understand the role diabetes treatments may play in patients' cardiovascular health," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "In addition to retrospective analyses like this one, our EXSCEL cardiovascular outcomes study is underway to thoroughly and prospectively evaluate cardiovascular effects of exenatide."

EXSCEL (EXenatide Study of Cardiovascular Event Lowering) is designed to determine if there are favorable cardiovascular effects of exenatide treatment, using BYDUREON™ (exenatide extended-relea
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
(Date:7/10/2014)... 3 fatty acids had healthier joints than those fed ... acids, according to Duke Medicine researchers. , The findings, ... (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that unhealthy ... to worsening osteoarthritis. , "Our results suggest that dietary ... in the link between obesity and osteoarthritis," said Farshid ...
(Date:7/10/2014)... 10, 2014 Ticketability.com has a wide array ... Paul McCartney tickets for San Diego are being added to ... since 1976, and the newly added September 28 show is ... Click Here to view the selection of discounted ... Park will become available to the general public on July ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 In his ... speaker and drug treatment facility CEO Per Wickstrom has ... “Whether we’re trying to confirm an appointment, get information ... is that following-up without being annoying is a skill ... there is a way to keep the dialogue moving ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Parker ... protecting the rights of victims injured by defective ... a lawsuit over allegations that the woman’s hidden, ... a power morcellator used during a routine laparoscopic ... against Richard Wolf Medical Instruments Corporation over its ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... Ill., Nov. 15 Winston,Laboratories, Inc., a specialty ... products for pain management, and Getting,Ready Corporation (OTC ... operations, have signed a merger agreement that will ... company will be renamed,Winston Pharmaceuticals, Inc., and will ...
... International,Technology Inc. (MDLH. PK) ( http://www.mitcanada.ca , http://www.mitinvest.ca ... completed its,10QSB quarterly reports (December 2006, March 2007 ... with its filings. Medical International Technology Inc. ... means to help prevent the spread of deadly ...
... can lead to under-reporting when applying for driver,s licenses, ... In patients with focal epilepsy, simply asking how often ... their seizure frequency, German research suggests. , Reminding patients ... help, either, because they may be unaware of some ...
... simplex virus type 2 (HSV-2) and HIV revealed that drugs ... the blood and rectal secretions, which may make patients less ... in the November 15 issue of the Journal of Infectious ... are also infected with HSV-2, which is the major cause ...
... year due to ... lung cancer --, -- More than 50% of new patients have ... according to the Lung Cancer Alliance --, ... early cancer detection, and The Thomas,G. Labrecque Foundation, a nonprofit organization that funds lung ...
... and Free Test Kits at the Radisson in Celebration, ... are,invited to a free Alpha-1 Education Day on Saturday, ... Radisson Resort Orlando - Celebration, located at,2900 Parkway Blvd. ... one of the most common,life- threatening genetic disorders, but ...
Cached Medicine News:Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 2Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 3Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 4Health News:Some Epilepsy Patients Not Always Aware of Seizures 2Health News:Study shows suppressing herpes virus may reduce infectiousness of HIV 2Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 2Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 3Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 4Health News:Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1 2
The SURGIWIP™ suture ligature with delivery system is indicated for use in gynecologic, general and other abdominal and thoracic endoscopic procedures where a suture is appropriate for the endo...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: